Related Experiment Videos
Zonisamide monotherapy in a multi-group clinic.
Michael E Newmark1, Stephanie Dubinsky
1Department of Neurology, Kelsey-Seybold Clinic, Houston, TX 77025, USA. Menewmark@kelsey-seybold.com
Seizure
|May 4, 2004
Summary
Zonisamide monotherapy is safe and effective for various seizure types in both new and previously treated patients. This study shows its suitability as a first-line antiepileptic drug therapy.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Limited reports exist on zonisamide monotherapy, primarily from specialized centers.
- Preliminary data suggest favorable outcomes for zonisamide use.
Purpose of the Study:
- To evaluate clinical experience with zonisamide monotherapy.
- To assess its efficacy and tolerability in a large, multi-group clinic setting.
Main Methods:
- Retrospective chart review of 54 patients (pediatric and adult) treated with zonisamide monotherapy.
- Analysis of two subgroups: antiepileptic drug (AED)-naive patients and those with prior AED exposure.
Main Results:
- 70.4% of patients continued zonisamide monotherapy.
- 24 patients achieved seizure freedom, with 11 on a 100-mg initial dose.
- Zonisamide monotherapy was well-tolerated across both patient groups.
Conclusions:
- Zonisamide monotherapy demonstrates safety and efficacy for diverse seizure types.
- It may be a viable first-line treatment option for select patients.